The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia

MLA

Ann-Katrin Eriksson, et al. “The Novel Tyrosine Kinase Inhibitor AKN-028 Has Significant Antileukemic Activity in Cell Lines and Primary Cultures of Acute Myeloid Leukemia.” Blood Cancer Journal, vol. 2, Aug. 2012, p. e81. EBSCOhost, https://doi.org/10.1038/bcj.2012.28.

APA

Ann-Katrin Eriksson, Monica Hermanson, Elin Lindhagen, C Ekholm, Fredrik Lehmann, Martin Höglund, Malin Wickström, A Jenmalm Jensen, Rolf Larsson, Vendela Parrow, & A Löthgren. (2012). The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. Blood Cancer Journal, 2, e81. https://doi.org/10.1038/bcj.2012.28

Chicago

Ann-Katrin Eriksson, Monica Hermanson, Elin Lindhagen, C Ekholm, Fredrik Lehmann, Martin Höglund, Malin Wickström, et al. 2012. “The Novel Tyrosine Kinase Inhibitor AKN-028 Has Significant Antileukemic Activity in Cell Lines and Primary Cultures of Acute Myeloid Leukemia.” Blood Cancer Journal 2 (August): e81. doi:10.1038/bcj.2012.28.